RxDoctor Payments Data

Jeffrey Johannes, PA

Physician Assistant · Omaha, NENPI 1346203049

Payments from drug & device makers

$5,209in general payments, 2019–2025

Across 289 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$621
  • Lilly USA, LLC$445
  • Novo Nordisk$306
  • Amgen$281
  • Takeda Pharmaceuticals U.S.A., Inc.$216
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,209100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,209 in reported general payments places this provider in the 90th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$58,764
Medicare patients
412
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl11$23,538
LinzessLinaclotide33$20,332
EliquisApixaban24$14,149
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,207
Doxycycline Hyclate79$770
Levothyroxine Sodium74$604
Gabapentin51$604
Potassium Chloride49$547
Albuterol Sulfate HfaAlbuterol Sulfate31$534
Omeprazole33$518
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$442
Atorvastatin Calcium67$407
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$351
Metoprolol Succinate27$328
Nystatin12$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,332$20,33233 claims
PfizerEliquis$163$14,14924 claims
GSKTrelegy Ellipta$28$9,20712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →